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Transcriptional regulationCells are constantly exposed to a large variety of lipids. Traditionally, thesemolecules were thought to serve as
simple energy storing molecules. More recently it has been realized that they can also initiate and regulate
signaling events that will decisively inﬂuence development, cellular differentiation, metabolism and related
functions through the regulation of gene expression. Multicellular organisms dedicate a large family of
nuclear receptors to these tasks. These proteins combine the deﬁning features of both transcription factors
and receptor molecules, and therefore have the unique ability of being able to bind lipid signaling molecules
and transduce the appropriate signals derived from lipid environment to the level of gene expression.
Intriguingly, the members of a subfamily of the nuclear receptors, the peroxisome proliferator-activated
receptors (PPARs) are able to sense and interpret fatty acid signals derived from dietary lipids, pathogenic
lipoproteins or essential fatty acid metabolites. Not surprisingly, Peroxisome proliferator-activated receptors
were found to be key regulators of lipid and carbohydrate metabolism. Unexpectedly, later studies revealed
that Peroxisome proliferator-activated receptors are also able to modulate inﬂammatory responses. Here we
summarize our understanding on how these transcription factors/receptors connect lipid metabolism to
inﬂammation and some of the novel regulatory mechanisms by which they contribute to homeostasis and
certain pathological conditions. This article is part of a Special Issue entitled: Translating nuclear receptors
from health to disease.slating nuclear receptors from
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Early in the '90s it was observed that several distinct compounds
with similar chemical properties were able to trigger both an increase
in size and number of hepatic and renal peroxisomes in rodent cells.
Treatment of rodents with these compounds also increased the rate of
β-oxidation of fatty acids and caused hepatomegaly and carcinogen-
esis, which did not occur in humans [1]. These compounds included
certain herbicides, phthalate plasticizers and, most importantly, the
ﬁbrate class of hypolipidemic drugs [2,3], which were later termed as
peroxisome proliferators. The search for the pharmacophores whose
activation by peroxisome proliferators caused the above effects led to
the identiﬁcation of peroxisome proliferator-activated receptor alpha
(PPARα), a novel member of the nuclear receptor hormone
superfamily [1]. Based on sequence homology, the genes for two
othermembers of the PPAR subfamily, PPARγ and PPARβ/δ, were latercloned from the mouse genome [4–6]. All three subtypes of the PPAR
subfamily were found to be highly expressed in tissues relevant to
energy homeostasis, and since certain dietary fatty acids and their
metabolic derivatives were found to activate PPARs, the idea was
instantly formulated that PPARs were regulators of metabolism. The
validity of this suggestion was thoroughly proven in human and
mouse studies revealing that PPARs are indeed master regulators of
metabolism [7]. Later, better understanding of the expression pattern,
activity and biology of these transcription factors indicated that they
also have diverse functions outside of the realm of metabolism. Not
surprisingly, among these non-canonical PPAR functions the regula-
tion of inﬂammation has received the most attention and has been
the focus of intense research effort. Numerous studies indicate that
PPARs have anti-inﬂammatory effects in a wide range of pathological
conditions. This review aims to summarize both the fundamental
ﬁndings of PPAR biology and the advances in the understanding of
PPARs' functions in inﬂammatory responses.
2. Lipid biology and inﬂammation
Inﬂammation is a multistep process by which the host responds to
the perturbation of homeostasis. Microbial infections, injuries or
altered physiological conditions all have the potential to trigger an
Fig. 1. Number of publications on the role of PPARs in different types of inﬂammation.
PubMed search was carried out with the combinations of the names of PPAR subtypes
and certain inﬂammatory conditions. The total area of the pie diagrams correlates with
the number of publications found (without reviews). Total number of publications
(in parentheses) and percentage distribution of the three PPAR subtypes are indicated.
The size of the sectors indicates the number of publications on distinct subtypes in
inﬂammatory conditions.
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tion, a resolution phase ensues in which the damaged surrounding
tissue is repaired and homeostasis is restored. Inﬂammatory reactions
can be divided into acute inﬂammation, which is resolved in a rel-
atively short time, hours or days, and chronic inﬂammation, which
occurs over a longer period of time. Typically, chronic inﬂammatory
reactions develop gradually from an acute reaction if the host is not
able to eliminate the inﬂammatory inducer (for a review of inﬂam-
mation, see [8]). There is another form of chronic inﬂammatory
response, which is not linked to an acute event. Altered homeostatic
conditions, such as obesity and the related type 2 diabetes, or ath-
erosclerosis, exhibit certain features of an ongoing low grade systemic
chronic inﬂammation, including elevated levels of inﬂammatory
cytokines or acute phase proteins produced by the liver.
An inﬂammatory reaction can be regulated in a number of
different ways. The detection and interpretation of inﬂammatory
signals, the response of the activated immune cells (such as cytokine
release), the reaction of the surrounding tissue to inﬂammatory
agents and to immune mediators as well as the resolution/repair
phase are all targets of regulatory mechanisms. Interestingly, several
regulatory mechanisms of the inﬂammatory reaction were demon-
strated to be inﬂuenced by lipid molecules. Due to the fact that PPARs
are specialized receptors to detect fatty acid derived signal molecules,
they are key candidate for being the receptors that transduce a
fraction of the lipid mediated inﬂammatory signaling events. Indeed,
several instances were identiﬁed in which certain fatty acid derived
molecules were shown to activate PPARs and modulate inﬂammation
[9,10]. The best example of this might be the case of eicosanoids. It
has been known for a long time, that eicosanoids, the products of
the essential fatty acid metabolism, are potent inﬂammatory agents
that act locally to modulate inﬂammation. The simpliﬁed picture
suggests that eicosanoids are pro-inﬂammatory mediators that act
locally to enhance vasodilatation and increased permeability of
venules. However, a few examples of anti-inﬂammatory eicosanoids,
such as lipoxins, have also been described (for a review see [11]).
Additionally, it was found that a gradual shift in the eicosanoid proﬁle
of inﬂammatory reactions resulted in diminished production of the
initially predominant pro-inﬂammatory leukotrienes and increased
release of pro-resolution lipoxins in the course of the inﬂammatory
reaction [12]. Importantly, certain eicosanoids can signal not only via
their own cell surface receptors, but also via PPARs, suggesting that
the regulatory effects of these eicosanoids are partly mediated by
PPARs. Recently, emerging evidence has suggested that another class
of fatty acid molecules may also have dual potential to activate PPARs
and modulate inﬂammation. Dietary fatty acids have been regarded
solely as energy source for a long time, but they are now also rec-
ognized as regulators of inﬂammation (often via the modulation of
eicosanoid synthesis). For instance, saturated fatty acids and different
classes of polyunsaturated fatty acids (PUFAs) were demonstrated to
modulate inﬂammation [13]. Again, it is highly probable that PPARs
playmajor roles in transducing the signals derived from dietary intake
of lipids to the level of immune regulation.
The role of PPARs in inﬂammation is especially relevant in the
case of metabolic syndrome and atherosclerosis. These are diseases of
lipid (and glucose) metabolism with an underlying inﬂammatory
component. Metabolic syndrome is a cluster of symptoms (impaired
glucose tolerance, high blood pressure, dyslipidemia and abdominal
obesity) that are often associated and signiﬁcantly increase cardio-
vascular risk. Currently two main competing theories are proposed
that could explain the emergence of impaired glucose tolerance in
these patients. The lipotoxicity theory [14] proposes that when the fat
storing capacity of the adipose tissue is chronically overloaded, fatty
molecules will be deposited in other tissues, including muscle and
liver. This would cause impaired insulin signaling in these tissues and,
as a result, would lead to impaired glucose tolerance. The alternative
explanation suggests that chronic caloric overload initiates an inﬂam-matory response that is originated in the adipose tissue [15,16]. The
inﬂammatory reaction make adipocytes and immune cells residing in
the adipose tissue produce cytokines and adipokines (such as tumor
necrosis alpha (TNFα)) that could lead to impaired glucose tolerance
in remote tissues of the body [17]. Regardless of the nature of the
primary mechanism, chronic inﬂammation seems to be an important
component of metabolic disease. Synthetic PPARγ agonists (the
glucose sensitizing thiazolidinedione (TZD) drugs) are potent drugs
that improve insulin sensitivity in metabolic syndrome [18]. These
drugs act primarily by modulating lipid and glucose metabolism, but
they also have well documented anti-inﬂammatory effects as well.
It is possible that PPARγ ameliorates metabolic syndrome solely by
improving metabolic activities of target tissues involved in carbohy-
drate and lipid metabolism, as well as fat storage. It is also possible,
however, that the beneﬁcial effects of PPARγ activation on insulin
sensitivity are mediated, at least partly, by its anti-inﬂammatory
activities.
Due to their role in the above medical conditions, the metabolic
roles of PPARs have been the target of intensive research. As their
functions in inﬂammation slowly emerged, an increasing number of
studies were devoted to dissect the role of PPARs in different types of
inﬂammation, as well (Fig. 1).
3. General biology of nuclear receptors
As already noted, PPARs belong to the nuclear receptor hormone
superfamily. These proteins are transcription factors that are not
only able to bind to DNA and regulate gene expression but they also
serve as intracellular receptors by binding lipid molecules. This
superfamily emerged in the early metazoan evolution and underwent
an intensive evolutionary divergence [19,20]. As a result, the human
and the mouse genome contain genes for 48 or 49 different nuclear
receptors, respectively. A series of gene duplication events during
early vertebrate evolution produced (among other subfamilies) the
three members of the PPAR subfamily. There are several ways to
group and categorize the divergent members of the superfamily.
Originally those nuclear receptors whose ligands were identiﬁed
were called “classic” nuclear receptors. These are typically endocrine
receptors that bind their ligands with high afﬁnity (such as thyroid
hormone receptors for the thyroid hormones or the estrogen
receptors for estrogens). Other nuclear receptors, whose ligands
remained unknown, were classiﬁed as orphan nuclear receptors. To
compound the naming system, the cognate ligands of some orphan
nuclear receptors (including PPARs) were originally unknown but
Table 1
PPAR ligands. See text for details.
Receptor Endogenous ligands Synthetic ligands
PPARα Saturated fatty acids, unsaturated
fatty acids, leukotriene B4, 8-HETE
Cloﬁbrate, fenoﬁbrate,
gemﬁbrozil, Wy-14643
PPARβ/δ Saturated fatty acids, unsaturated
fatty acids, 15-HETE, components
of VLDLs
GW-501516
PPARγ Unsaturated fatty acids, 15d-PGJ2,
15-HETE, 9-HODE, 13-HODE,
components of oxLDLs
TZDs (rosiglitazone, pioglitazone,
troglitazone and ciglitazone),
farglitazar, tyrosine derivatives,
NSAIDs
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later group of orphan nuclear receptors became “adopted” and was
often referred to as adopted nuclear receptors [21]. This classical
grouping system of nuclear receptors has several weaknesses. Maybe
the biggest source of inconsistency in this classiﬁcation derives from
the fact that those nuclear receptors are categorized as orphanswhose
ligand has not been found yet. Since novel ligands are found and
characterized all the time, this classiﬁcation is, by its very nature,
always temporary. Reﬂecting on the weaknesses of the above clas-
siﬁcation principle based on the presence of endogenous ligands, a
phylogenetic classiﬁcation model was introduced [22] in which
the main organizing principle was sequence similarity. In this new
nomenclature nuclear receptors received novel acronyms that
reﬂected their position in the phylogenetic tree. Accordingly,
PPARα, PPARβ/δ and PPARγ were renamed as NR1C1, NR1C2 and
NR1C3, respectively. Although it would be more accurate to refer to
PPARs according to this new naming system in the literature
(including this review), we will use their trivial names to avoid
confusion. One can assume that nuclear receptors that are very close
on the phylogenetic tree and are therefore highly related show similar
ligand binding properties and fulﬁll similar cellular roles. As their
novel nomenclature indicates, the three different subtypes of PPAR
show relatively high similarity. It would be tempting to assume
therefore that they have similar functions. However, this is certainly
not true for their main action, namely the regulation of metabolism,
in which PPARα, an activator of mitochondrial and peroxisomal
fatty acid β-oxidation in liver, PPARβ/δ, a regulator of fatty acid
oxidation inmuscle and PPARγ, an activator of fatty acid synthesis and
storage, play divergent roles in metabolism. Surprisingly, the
emerging body of studies on the inﬂammatory roles of the three
PPAR subtypes suggests that all the three PPARs have, for the most
part, anti-inﬂammatory activities. How the three PPAR subtypes, with
divergent metabolic roles and distinct transcriptional activities, can
have highly overlapping anti-inﬂammatory proﬁles is an open question.
4. Introduction to PPARs
As noted earlier, there are three subtypes of PPARs in vertebrates,
PPARα (NR1C1), PPARβ/δ (NR1C2) and PPARγ (NR1C3). Mouse
PPARαwas cloned ﬁrst, which was followed by the cloning of all three
subtypes from Xenopus and other vertebrate genomes [4–6,23–26].
The naming of the mammalian homologues of PPARα and PPARγ
was evident because they showed high degree of similarity to their
counterparts found in the Xenopus. Mammalian PPARβ/δ, however,
showed considerable divergence at the sequence level from the
Xenopus PPARβ. Because of the lesser degree of sequence homology,
this subtype in the mammals was alternatively named as PPARβ,
PPARδ, FAAR, NUC1 or PPARβ/δ.
4.1. Ligands of PPARs
PPARs were originally described as orphan nuclear receptors, but
soon a plethora of potential endogenous ligands were described.
There are two major class of assays used to identify ligands. One class
is represented by in vitro transactivation assays. In these cellular
assays nuclear receptors are expressed ectopically in cells and the
candidate ligands are used to activate the receptors. A marker of the
transactivation activity of the nuclear receptor is then measured. This
marker could be e.g. a known target gene for the corresponding
receptor, or a signal that derives from an expression construct where
a PPAR target sequence linked to a core promoter and a reporter (e.g.
luciferase) gene. The second class of methods comprises biophysical
techniques that measure the physical binding of candidate ligands to
the receptors (e.g. radioligand competition assays, the Scintillation
Proximity Assay (SPA), the Ligand Induced Complex (LIC) assay or the
Coactivator Dependent Receptor Ligand Assay (CARLA)). The detaileddescription of these methods is outside the scope of this review.
However, it is important to note that both classes of techniques carry
their own weaknesses. When a candidate ligand causes enhanced
gene expression in transactivation assays it is difﬁcult to determine
whether the candidate ligand itself binds to the receptor. Alternative
explanations for the enhanced transactivation activity can be that the
candidate ligand is actually a precursor of a true ligand, or that it
initiates signaling events that will culminate in generating an
unidentiﬁed ligand. The weakness of the biophysical methods is
that although they provide a direct proof for the binding of a
candidate ligand to the receptor, they do not guarantee that these
molecules are present in the cells at high enough concentrations to
serve as effective endogenous ligands. Indeed, most of the putative
ligands are required to be present in vivo at such a high concentra-
tions to efﬁciently activate PPARs that their function as bona ﬁde
PPAR ligands is often questioned. This leads to the paradox situation
that although numerous ligands are suspected to be PPAR activators,
the real identity of true endogenous ligands of PPARs is still very
much debated. Here we provide a short summary of the major groups
of the candidate PPARs ligands. More detail regarding the ligands
of different PPAR subtypes will be provided in the corresponding
sections.
Due to the fact that three subtypes do not show strict ligand
speciﬁcity, it is logical to discuss the ligands of all PPAR subtypes
together (Table 1). If a certain ligand is able to activate one subtype,
then the same molecule is often found to bind to or activate the other
subtypes at various efﬁciencies. Therefore a key feature of PPARs
appears to be that they act as receptors that have numerous ligands
that each binds to the receptors with relatively low afﬁnity. This is in
stark contrast with the case of the classic nuclear receptors (e.g.
estrogen receptor or glucocorticoid receptor) that bind a very limited
number of highly speciﬁc ligands at high afﬁnity. This promiscuous
ligand binding of PPARs is also reﬂected in the size of the ligand
binding pocket of the PPAR proteins. The ligand binding pocket of
PPARs is characteristically larger than that of classic nuclear receptors.
It is possible that the unusually large ligand binding pocket enables
PPARs to bind such a variety of different ligands.
Molecules that were found to bind physically to PPARs include
polyunsaturated fatty acids (PUFAs) suchas certainω3-polyunsaturated
fatty acids (e.g. α-linolenic acid with C18:3, or docosahexaenoic acid
with C22:6), and certain ω6-polyunsaturated fatty acids (such as
linoleic acid with C18:2 and arachidonic acid with C20:4). Certain
saturated fatty acids (such as myristic acid with C14:0 and stearic acid
with C18:0) were also found to bind to PPARα. The ﬁnding that dietary
fatty acids can bind to and activate nuclear receptors and regulate gene
expression akin to small molecule endocrine hormones caused a
paradigm shift in how we think about the role of dietary fatty acids.
Another group of PPAR ligands comprises the conversion products of
essential fatty acids (mainly arachidonic acid) by lipoxygenases or
cyclooxygenases. The best examples for eicosanoids that are possibly
PPARα ligands are hydroxyeicosatetraenoic acids (e.g. 8(S)-HETE) and
leukotriene B4 (LTB4), while prostacyclin (PGI2) [27], an eicosanoid
with platelet activation inhibiting activity, is a possible endogenous
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deoxy-Δ12,14-prostaglandinJ2 (15d-PGJ2) and components of oxi-
dized low-density lipoproteins, hydroxyoctadenoic acids (9-HODE and
13-HODE) are suspected PPARγ ligands [27–32]. Recent ﬁndings raised
the interesting idea if PPARs are not speciﬁc receptors for one particular
fatty acid molecule but are sensor molecules that sample the
intracellular mixture of available fatty acid species. In line of this idea,
Itoh et al. raised the possibility that PPARγ covalently binds a subset of
fatty acids and that PPARγ can bind two ligand molecules at the same
time [33]. The involvement of PPARs in detecting the fatty acid milieu
was further supported in a study that demonstrated that PPARβ/δ is a
hepatic free fatty acid sensor in the mouse [34].
Which of the above mentioned candidate ligands are bona ﬁde
endogenous ligands? To answer this question it would be necessary
to know which candidate molecules are present intracellularly at a
concentration that is in good agreement with their dissociation
constant (Kd) values. Not only is this a technically extremely
challenging task, but it is not fully understood how these lypophilic
molecules are transported across the cell membrane, stored or
metabolized in the cells. It is possible that certain candidate ligands
that are present at low extracellular concentrations (which would
seemingly preclude them from being endogenous ligands) can reach
high concentrations locally. Among the candidate ligands listed above,
the polyunsaturated fatty acids that can bind to PPARs are potentially
true endogenous ligands for PPARα. It is less certain if any of the
saturated fatty acids can work as ligands for PPARs. The eicosanoids
(such as 8(S)-HETE for PPARα, 15d-PGJ2 for PPARγ and 15-HETE for
PPARβ/δ) are often cited as lipidmetabolites that have the potential to
reach high enough concentrations to activate PPARs [35]. In summary,
despite the large number of candidate endogenous ligands the true
identity of the bona ﬁde ligand(s) for PPARs is highly controversial.
PPARs also have synthetic ligands that can easily be used to
interrogate the transcriptional activities of the PPARs in cells that
express different subtypes of PPARs. All three subtypes have highly (but
not exclusively) speciﬁc agonists [18,27,36–38]. Good examples are the
hypolipidemic drugs cloﬁbrate and fenoﬁbrate, the potent synthetic
ligand Wy-14643 for PPARα, the thiazolidinedione (TZD) group of
antidiabetic drugs (including troglitazone, pioglitazone, ciglitazone
and rosiglitazone (formerly known as BRL 49653)) for PPARγ and
GW-501516 for PPARβ/δ. PPARγ also has a speciﬁc synthetic antagonist,
calledGW-9662. Certain nonsteroidal anti-inﬂammatorydrugs (NAIDS)
were also shown to activate PPARγ [39]. These drugs (including
indomethacin, ibuprofen and fenoprofen) are cyclooxygenase inhibi-
tors, but they have certain effects that could not be ascribed to inhibition
of cyclooxygenases.
4.2. DNA recognition by PPARs
PPARs form heterodimers with their obligate partners, the
members of another subfamily of nuclear receptors, RXRs (of which
three subtypes exist, RXRα, RXRβ and RXRγ). According to the
simpliﬁed model, upon ligand binding PPAR/RXR heterodimers
recognize and bind to speciﬁc DNA sequences, called PPAR response
elements (PPRE) [40]. This PPRE is a direct repeat of six nucleotide
long core recognition motives (AGGTCA) that are separated by a
single nucleotide. Because of the orientation and distance of the two
hexameric motives, the PPRE is also called DR1. There are some
additional features of PPAR target sites, such as the presence of an
extended 5-half site, the presence of adenine as the separator single
nucleotide or a slightly imperfect hexameric motif [41]. It is important
to note, however, that the exact features of the consensus PPREs
were calculated from DNA sequences to which PPARs were shown to
bind and on which they acted as transactivators. The consensus
sequence was derived from the 5′ region of known PPAR target gene
transcriptional start sites that showed robust regulation by PPARs.
Due to the fact that PPARs (and other nuclear receptors) can bind toDNA in both orientation and at an unpredictable distance to their
target genes, it is possible that the ﬁne features of the DR1 elements
were calculated from sequences that were not perfectly representa-
tive to all PPREs. Novel experimental approaches, such as “ChIP-on-
chip” or “ChIP-seq” that are based on determining the sequence of the
DNA binding sites of chromatin immune-precipitated transcription
factors hold the potential to identify and fully characterize PPREs at
the whole genome level [42,43].
All three PPAR subtypes are believed to bind to canonical DR1
elements. Due to the fact that certain cell types express more than
one PPAR subtype, the question arises what determines PPAR binding to
a certain DR1 element in these cells [44]. Results showed that the
5′ﬂankingnucleotidesof thecoreDR1elementsplayedan important role
in determining the PPAR subtype speciﬁcity of PPREs. Still, these ﬁne
additional sequence features cannot make PPREs entirely subtype
speciﬁc. Accordingly, there are only a very few, if any, PPAR responsive
genes that can only be regulated by one subtype of PPARs. A recent
example of a subtype speciﬁc response elementwas shown to be present
in the fatty acid bindingprotein 4 (FABP4/aP2) gene [45] that is under the
exclusive control of PPARγ in macrophages but not in adipocytes.
A further twist in the recognition of DR1 elements by PPAR-RXR
heterodimers is the fact that the heterodimeric partner, RXR, is also a
nuclear receptor and has its own cognate ligand (e.g. 9-cis retinoic acid
or various fatty acids). It is possible that in cells in which there is no
PPAR ligand available but RXR ligands are present, functional PPAR-RXR
heterodimers can still bind to DR1 elements and regulate gene
expression. When and to what extent this might happen is a complex
question, and could be inﬂuenced by the target gene, the cell type and
possibly by uncharacterized ﬁne features of DR1 elements [46].
4.3. Experimental models for studying PPAR functions
One of the reasons why PPARs have been studied very intensively
is that synthetic ligands of PPARα and PPARγ have been commonly
used to treat metabolic diseases, such as dyslipidemia and type 2
diabetes, respectively, that affect millions of patients worldwide. As a
result, the early studies focused on the metabolic actions of PPARs.
Concomitant to the experimental studies, enormous amount of data
accumulated over the years about the long termmedical effects of the
pharmacological activation of PPARs. This wealth of information can
give us a head start in understanding the functions of PPARs in ﬁelds
not directly related to metabolism.
There are several types of experimental approaches from which
we have learned a great deal about the inﬂammatory roles of PPARs.
The simplest approach is to analyze transcriptional events in cells in
which PPARs are activated by ligand treatment. Synthetic agonists
are available for each PPAR subtypes. Additionally, a very speciﬁc
antagonist for PPARγ also exists. The availability of these compounds
gives us a unique opportunity to study these transcription factors. The
fact that agonists for PPARα and PPARγwere characterized ﬁrst partly
explains why we know much more about the functions of these
PPARs. It must be noted, however, that results based on transcrip-
tional proﬁling of agonist treated cells can be misleading. Although
PPAR ligands are highly (subtype) speciﬁc for the most part, it is also
well documented that there are agonist effects that are mediated by
the other PPARs or not mediated by PPARs at all, especially when
these agonist are applied at very high concentrations.
PPAR functions can also be studied in animal models of disease.
There are genetically modiﬁed mouse strains available for each PPAR.
Whole body knockout of PPARα causes relatively minor phenotypes
in unchallenged animals [47,48]. PPARβ/δ knockout animals display
high embryonic mortality on inbred background [49]. PPARγ−/−
animals are not viable and die in utero due to the deleterious effects of
PPARγ deﬁciency in placentation. As a corollary, deﬁciency in PPARγ
(and partly in PPARβ/δ) can be studied in heterozygous animals or in
mice in which the PPARγ gene is disrupted by a Cre/lox mediated
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PPARγ is deleted only in e.g. macrophages, T cells or adipocytes, are
viable and breed easily, but often show increased susceptibility to
different experimentally induced diseases. A recently applied strategy
used to circumvent the deleterious effects of placental PPARγ deﬁciency
makes it possible to generate full body PPARγ knockout animals in
which PPARγ functions are preserved in placental trophoblasts but lost
in virtually all embryonic tissues. In these mouse models the Cre
recombinase was under the control of the Mox or the Sox2 promoter
[52,53]. The latter model appears to be superior due to a more
throughout recombination in the embryo proper. The role of PPARs in
various diseases can also be studied by treating wild type animals, in
which distinct diseases are developed experimentally, with PPAR
ligands. Again, agonists were found to have considerable off-target
effects in the animal studies. As a result, effects of agonist treatments in
wild type animals can only be ascribed to PPAR mediated functions if
these effects are not detectable in PPAR deﬁcient animals.
Finally, clinical studies, medical practice and human genetics
are also important sources of information that can help dissect the
functions of PPARs. Millions of people worldwide have been treated
with synthetic agonists of PPARγ for impaired glucose tolerance, or
with PPARα agonists to normalize serum lipid levels. Statistical
analysis of the incidence of diseases where PPARs are implicated can
corroborate or refute results derived from cellular or animal studies.
4.4. Mechanism of the inﬂammatory actions of PPARs
Cellular and in vivo studies suggest that PPARs can exert their anti-
inﬂammatory effects by several distinct molecular mechanisms
(Fig. 2). As transcription factors, their canonical regulatory mecha-
nism is transactivation, by which ligand activated PPARs bind to their
recognition sequences and regulate gene expression. Another form of
gene regulation by PPARs is transrepression. During transrepres-
sion, PPARs bind and sequester other, unrelated transcription factors
or transcriptional regulators. As a net result of this sequestration,
regulatory circuits regulated by the relevant transcription factors
will be impaired. Such transrepression mechanisms have been
described for each subtype of PPARs. PPARα and PPARγ were
described to transrepress other transcription factors when they areFig. 2.Mechanisms of genetic regulation by PPARs. (A) Upon ligand binding, PPARs induce ge
of gene expression by transactivation. Liganded PPAR/RXR heterodimers recruit co-activator
gene expression. (B) A subset of direct target genes might be repressed by PPARs in the pres
regulations result in activation. (C) Ligand dependent trans-repression by PPARs. Upon ligan
NF-κB, through protein–protein interactions. (D) Ligand independent transrepression. Unl
typical example for such a mechanism is the binding of BCL-6 by unliganded PPARβ/δ. (E) PPA
transcription factors.activated by ligand binding. On the other hand, most of the known
anti-inﬂammatory effects of PPARβ/δ are mediated by ligand
independent transrepression.
How are the molecular mechanisms of PPAR activity translated
into anti-inﬂammatory effects? It is possible that PPARs regulate the
expression of genes (either directly or indirectly, through transre-
pression) that have direct inﬂammatory roles. Alternatively, it is
also possible that PPARs modulate inﬂammatory processes indirectly
by altering lipid metabolism. According to this scenario, PPARs would
directly modify the intra-, and extracellular pool of lipid molecules
available in the body, and this altered lipid environment would
initiate secondary regulatory processes. Such a mechanism is
described in human dendritic cells (DCs) [54] where activation of
PPARγ leads to the generation of retinoic acid, a molecule that
regulates DC phenotype. It must be noted that the three PPAR
subtypes alter intra-, and extracellular lipid homeostasis in distinct
ways. PPARα is activated and provides energy from fatty acid
catabolism during starvation and cold acclimatization, PPARγ is
activated in the well fed state and regulates the synthesis of fatty
acids and related lipids, while PPARβ/δ ensures, among other, that
fatty acids can provide energy for working muscles. How the three
subtypes of PPAR that alter lipid metabolism in three distinctly
different ways and generate distinct classes of lipid molecules can
have similar anti-inﬂammatory roles in diseases suggest that the
regulatory circuits of PPARs in metabolism and inﬂammation are, at
least partly, uncoupled. It is also probable that the observed anti-
inﬂammatory effects of PPARs are not exclusively mediated through
their capacity to alter whole body lipid homeostasis and direct
molecular regulatory mechanisms are, at least partly, accountable
for their anti-inﬂammatory effects. In the next sections we provide a
short summary of the biology of the different subtypes and present a
subjective account of the inﬂammatory models in which PPARs were
implicated (Table 2)We limited our discussion to thosemodels where
molecular details of the regulatory mechanisms are accumulating.
5. PPARγ
There are two distinct isoforms of PPARγ, termed PPARγ1 and
PPARγ2, which are transcribed from the same gene. PPARγ2 differs byne expression. A subset of the induction, shown here, is the result of the direct regulation
molecules to promoters that contain PPAR response elements and subsequently activate
ence of ligands. However, the majority of characterized PPAR-mediated transcriptional
d binding, PPARs can interfere with the activity of distinct transcription factors, such as
iganded PPARs can bind and sequester transcription factors blocking their activity. A
Rs alter systemic lipid homeostasis which can affect gene regulation through unrelated
Table 2
Mouse inﬂammatory models and PPARs. Relevant inﬂammatory models and the involvement of PPAR subtypes are shown.
Experimental model PPARα Ref. PPARβ/δ Ref. PPARγ Ref.
Experimental autoimmune encephalomyelitis Ligand treatment:
↓severity
↑IL-4, ↓IFN-γ
↓NO production
[141,142,144] Ligand treatment:
↓severity
[143] Ligand treatment:
↓severity
↓IL-12, Th1/Th17 T cells
[106,107,109]
PPARβ/δ−/− mice:
↑severity
↑IFN-γ, IL-12
PPARγ+/− mice:
↑severity
Colitis Ligand treatment:
↓severity
↓INF-γ, IL-17
[137,159] Ligand treatment:
No effect
[155] Ligand treatment:
↓severity
[101,105]
PPARα−/− mice:
↑severity
PPARβ/δ−/− mice:
↑severity
PPARγ +/− mice:
↑severity
Carrageenan-induced Ligand treatment:
↓severity
[135] Ligand treatment:
↓severity
[160] Ligand treatment:
↓severity
[161]
edema (acute inﬂammation)
Atherosclerosis PPARα−/− mice:
↓/↑lesions
[147, 148] Ligand treatment:
↓lesions
[152] Ligand treatment:
↓lesions (only in males)
[111,113]
PPARα−/− BMT:
↑lesions
PPARγ−/− BMT:
↑lesions
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[55]. PPARγ2, which has a stronger transcriptional activity, is expressed
at a high level almost exclusively in the adipose tissue, while PPARγ1 is
expressed in a host of cell types (including adipose tissue, spleen, liver,
pancreas, retina, skeletal muscle, endothelia, vascular smooth muscle
cells, sebocytes/sebaceous glands, macrophages, dendritic cells and
lymphocytes [25,56–64]) at a lower expression level. PPARγ is an
important regulator of adipose tissue development, fatty acid synthesis
and insulin sensitivity of major glucose utilizing tissues. PPARγ is
required for adipocyte differentiation and for the maintenance of
differentiated adipocytes [65,66]. Not only was PPARγ found to be an
important regulator of adipose function, lipogenesis and lipid storage, it
was alsodemonstrated that theTZD class of drugs,which canbeused for
the treatment of type 2 diabetes, are cognate ligands of PPARγ. For this
reason PPARγ has received far the most attention among the PPARs.
Concomitantly to the studies on the role of PPARγ in metabolism, it was
soon realized that PPARγ was not only expressed in adipocytes, but
(although at much lower levels) in immune cells, as well. The fact that
PPARγ1was shown to be expressed in inﬂammatory cells and that there
was a groupof available synthetic agonists of PPARγ thatwere approved
as drugs (for the treatment of type 2 diabetes) raised the appealing
prospect that the same drugs could easily be used to modulate in-
ﬂammation as well.5.1. Mechanisms of PPARγ mediated gene regulation
The canonical PPAR activity is the ligand dependent transactiva-
tion, in which liganded PPARγ forms heterodimers with RXR, and
the PPARγ/RXR heterodimers recruit a large protein complex of co-
activators required for the regulation of transcription. With the help
of these co-activators, PPARγ/RXR heterodimers bound to PPREs in
the enhancers of target genes will modulate the activity of the
basal transcription machinery. This classic transactivationmechanism
is well characterized at the molecular level. It is believed that such
ligand mediated PPARγ transactivation usually results in the upreg-
ulation and not repression of the target genes.
There are alternative mechanisms by which PPARγ can regulate
gene expression. These alternative mechanisms are especially impor-
tant for the understanding of the regulation of immune response by
PPARγ. The reason behind this is that it is very difﬁcult to interpret
the role of PPARγ in the immune system solely based on the classic
transactivation model. No canonical inﬂammatory regulators have
been described so far that are robustly upregulated by agonist
activated PPARγ. Moreover, at least a subset of the anti-inﬂammatory
effects of PPARγ is due to ligand dependent gene repression, which isdifﬁcult to reconcile with the classic model of the agonist action of
positive regulation of gene expression.
There are a number of distinct mechanisms responsible for ligand-
dependent gene repression by PPARγ, all occur through the indirect
regulatory effects of ligand binding. The resulting negative regulation
of gene repression is termed trans-repression if PPARγ action is not
mediated by its binding to canonical PPRE target DNA sequences.
Maybe the best characterized model is the case of ligand dependent
transrepression of inﬂammatory genes. According to this model [67],
there is an inhibitory protein complex bound to the promoter of
inﬂammatory genes (e.g. NOS2 (inducible nitric oxide synthase 2))
that keeps these genes repressed in the absence of inﬂammatory
signals. For an efﬁcient expression of NOS2 upon LPS (lipopolysac-
charide) induced TLR4 (toll-like receptor 4) activation, two require-
ments must be met. First, the inhibitory complex must be removed
from the promoter, and only then can the key immune regulator NF-
κB (nuclear factor kappa-light chain-enhancer of activated B cells)
activate NOS2 expression. The removal of the inhibitory complex is
normally carried out by the ubiquitin proteasome system. In cells that
receive concomitant PPARγ ligand and LPS treatments, a fraction of
the liganded PPARγ will be SUMOylated on lysine K365. The
SUMOylated PPARγ will not be able to bind its regular heterodimer-
ization partner, RXR. Instead, it will bind to the repressor complex
located on the promoter of inﬂammatory genes. The binding of PPARγ
to these repressor complexes will block the ubiquitination and hence
the efﬁcient removal of the repressors. As a result, ligand bound
PPARγwill maintain the repression on the promoter of inﬂammatory
genes, such as iNOS2, even in the presence of active TLR4 signaling.
Other forms of transrepression also exist. PPARγ was shown to bind
directly other transcription factors, such as NF-κB or activator protein
1 (AP-1) [68,69], interfering with the DNA binding capacity of
these transactivators. Ligand activated PPARγ was also demonstrated
tomodulate p38mitogen activated protein (MAP) kinase activity [70].
Although the above mechanisms can explain a subset of the anti-
inﬂammatory effects of PPARγ, it cannot be excluded that positive
transcriptional regulation of inhibitory proteins, rather than trans-
repression of other transcription factors, play important roles in
ligand-induced repression. Furthermore, the in vivo relevance and the
contribution of these proposed mechanisms to the inhibition of gene
expression remains to be further established.5.2. Alternative activation of PPARγ
The consequence of ligand mediated activation of PPARγ can be
modulated by phosphorylation. The ﬁrst study described the
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phosphorylation, which reduced the transcriptional activity of PPARγ
[71], was observed upon exposure of cells to serum. Controversially, it
was also found that insulin potentiated the ligand dependent
activation of PPARγ via the action of MAP kinases, as witnessed by
the enhanced expression of the robust PPARγ target gene, aP2 (also
known as FABP4) [72]. PPARγ1 could also be phosphorylated at
serine-82 (which corresponds to serine-112 of PPARγ2) by epidermal
growth factor (EGF) and platelet derived growth factor [73]. Again,
this phosphorylation event attenuated the transcriptional activity of
the ligand bound PPARγ. The explanation for the observed divergent
effect of PPARγ phosphorylation at the relevant serine is lacking.
Recently a novel mechanism for the posttranslational modiﬁcation
of PPARγ was described [74]. In this study the cdk5 mediated
phosphorylation at serine-273 of PPARγ2 led to the dysregulation of
the expression of a number of metabolism related target genes in
adipocytes. Treatment of adipocytes with the synthetic PPARγ
agonist, rosiglitazone, hindered this phosphorylation and normalized
gene expression. Importantly, the genes whose expression was
perturbed upon serine-273 phosphorylation were known to be
relevant in metabolic regulation but did not necessarily belong to
the “canonical” genes that are robustly regulated by PPARγ agonists.
This is a completely novel angle of PPARγ biology, since until now
the synthetic PPARγ ligands (both in metabolism and in other ﬁelds,
including inﬂammation) were assumed to work according to either
the classical agonist or the transactivation models. In the new model,
agonist binding caused a conformational change in PPARγ, which
modiﬁed the activity of the receptor by blocking a distinct signaling
event. Importantly, two different synthetic ligands (rosiglitazone
and MRL24), with greatly different agonist activities, were used in
the study. In classical agonist studies that measure the expression
of target genes upon ligand treatment in cells, MRL24 was found to
be a weak agonist of PPARγ, compared to rosiglitazone. Yet, the two
ligands inhibited PPARγ serine-273 phosphorylation with similar
efﬁciency. This study raised several important questions. One
question is if the same type of serine-273 phosphorylation is im-
portant in other functions of PPARγ, e.g. in the regulation of in-
ﬂammation. This is possible because cdk5 was reported to modify the
antiproliferative effect of PPARγ [75] and also because cdk5 was
shown to be activated in adipocytes exposed to inﬂammatory signals.
The other question is how the gene expression changes caused by
the transactivation effect of synthetic ligands relate to the gene
expression changes inﬂuenced by the cdk5 mediated phosphoryla-
tion. The functions of PPARγ in different model systems are usually
interpreted based on the agonist action of synthetic ligands. It is
possible that the gene expression proﬁle of agonist treated cells does
not reﬂect all the important mode of actions of PPARγ because a
different set of genes regulated by a distinct receptor activity remains
undetected in these experiments. The ﬁnding that weak agonists
can work as potent regulators of the cdk5 phosphorylation can also
reignite the efforts to ﬁnd the true endogenous ligands of PPARγ. It is
possible that there are molecules that are weak agonists of PPARγ
(and therefore were dismissed as endogenous ligands) but are potent
regulators of the cdk5 mediated phosphorylation.
5.3. Cellular model systems to study the inﬂammatory functions of
PPARγ
Myeloid cells were the ﬁrst immune cells in which the expression
and the function of PPARγ were studied. Murine bone marrow
derived and peritoneal macrophages, as well as human monocytic
cells (U937) were included in these analyses. Bone marrow macro-
phages expressed PPARγ at very low levels, but thioglycolate elicited
peritoneal macrophages showed a marked upregulation of PPARγ.
Additionally, IFN-γ (interferon-gamma) activated macrophages that
also received PPARγ ligand treatment phenotypically resembledresting macrophages. The idea was tested if PPARγ is a negative
regulator of macrophage differentiation and activation. It was found
that treatment of IFN-γ activated macrophages with the synthetic
ligand rosiglitazone or with the endogenous ligand 15d-PGJ2 blunted
the expression of inﬂammatory genes, such as the inducible nitric
oxide synthase, gelatinase B and scavenger receptor A genes.
Interestingly, a number of target sites for immunologically relevant
transcription factors (AP-1, NF-kB and STAT1 (signal transducer and
activator of transcription-1)) were detected in the proximal and
distal promoters of the regulated genes. This suggested that liganded
PPARγ acted via transrepression of other transcription factors [76]. In
a similar study [77], a number of different eicosanoids that are
possible endogenous ligands for PPARγ (including 15d-PGJ2), and the
TZD drug troglitazone were used to antagonize the effects of different
inﬂammatory signals on human peripheral monocytes. The two un-
related inﬂammatory agents, LPS and phorbol myristate acetate
(PMA), did cause a similar upregulation of inﬂammatory mediators,
such as TNF-α, IL-1β (interleukin-1β) and IL-6 (interleukin-6). Inter-
estingly, however, the putative PPARγ ligand 15d-PGJ2 could block
the elevated release of the inﬂammatory mediators only when PMA
was used to activate monocytes. This suggested that PPARγmediated
inhibition of inﬂammation is speciﬁcally restricted to a deﬁned
molecular pathway used only by certain inﬂammatory agents.
In two other early studies human monocytes, the human
myelomonocytic cell lines THP1 and HL60 and murine lymph node
macrophages [31,58] were investigated. It was found that lipid
components of oxidized low density lipoprotein (oxLDL) were able
to activate PPARγ in HL60 cells differentiating along the macrophage
lineage, while the parent LDL particle did not have the same effect.
A screening assay that used the ligand binding domain of PPAR fused
to the DNA binding domain of Gal4 identiﬁed 9- and 13-HODEs, as the
oxLDL derived activators of PPARγ. Because high LDL-cholesterol
levels show strong correlation with atherosclerosis, it was proposed
the uptake of oxidized LDL by monocytes and the subsequent activa-
tion of PPARγ might contribute to the appearance of foam cells, the
early hallmarks of atherosclerotic lesions.
The above papers laid the foundation for the ﬁeld that has seen an
ever increasing number of publications on PPARγ functions in
myeloid cells since then. Paradoxically, these studies also shed light
on the controversies of the ﬁeld. One such controversy is that 15d-
PGJ2, the candidate endogenous ligand used in these and other
studies is not a very speciﬁc PPARγ ligand. Additionally, the ligand
concentration used to inhibit inﬂammatory responses were higher
than it would be expected based on the Kd value for the ligands. For
these reasons the involvement of the other PPAR subtypes (or other,
unrelated proteins) in mediating the effects of PPARγ ligands could
not be excluded. These points are very well illustrated by the ﬁndings
that showed that 15d-PGJ2 and TZD drugs were similarly effective in
inhibiting LPS induced inﬂammatory cytokine release in wild type as
well as in PPARγ−/− macrophages [78]. These results demonstrated
that PPARγ ligands (namely TZDs and 15d-PGJ2) could exert potent
anti-inﬂammatory effects via PPARγ independent mechanisms.
Another caveat in interpreting these and other data is the fact that
the observed gene expression changes are not in linewith the classical
model of positive regulation of target genes by ligand activated
PPARγ. Clearly, other models of PPARγ actions, such as ligand
dependent or independent trans-activation could be responsible for
at least a subset of gene expression changes mediated by PPARγ.
When the gene expression changes in rosiglitazone treated or
untreated murine peritoneal macrophages [79] were characterized,
only 8 genes showed modestly enhanced expression when macro-
phages were treated with high concentration of the synthetic ligand.
These genes (including the genes for CD36, adipose differentiation-
related protein (ADRP), carnitine palmitoyl transferase 1a (Cpt1a),
enoyl coenzyme A hydratase 1 (Ech1) and ATP binding cassette
subfamily G1 (ABCG1)) had known functions in lipid metabolism, but
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demonstrated that activation of PPARγ in murine macrophages
regulated the differentiation of the (IL-4 induced) alternative
activated macrophages (M2 macrophages). The ability of PPARγ to
control the alternative macrophage differentiation was partly medi-
ated by the transactivation of arginase I, a known regulator of the M2
development. The importance of PPARγ in regulating the balance of
classical/alternative macrophages in human was also demonstrated
by Bouhlel et al. who demonstrated that the level of M2 macrophages
in atherosclerotic lesions correlated with the expression level of
PPARγ [81]. Interestingly, Szanto et al. suggested that PPARγ is not a
regulator of alternative activation of macrophages per se, but is more
likely a downstream effector of the IL-4 signaling pathway [45]. They
found that Il-4 acted as a licensing factor for macrophage PPARγ
that promoted PPARγ DNA binding to a subset of PPARγ PPREs in
macrophages. Regardless of the signaling hierarchy of IL-4 and PPARγ
in M2 macrophage differentiation, PPARγ and IL-4 signaling seem to
be mechanistically linked. These reports can redirect the focus of the
macrophage PPARγ research from the regulation of classical macro-
phage activation to other macrophage functions, including alternative
macrophage activities. The function of the alternatively activated
macrophages is controversial. Due to the fact that alternatively
activated macrophages develop in Th2 type immune responses upon
macrophage exposure to IL-4 or IL-13, their in vivo function is
probably linked to IL-4/IL-13 driven processes. These cells have a
documented role in immunity against parasites [82,83] and in allergy,
and are often implicated in wound healing/repair, angiogenesis and
atherosclerosis [84]. The ﬁndings of Szanto et al. raise the question of
what is the relevance of the PPARγ–STAT6 interaction in lipid
metabolism, type-2 diabetes, atherosclerosis and the above, classical
IL-4 mediated diseases.
After the characterization of PPARγ in macrophages, a closely
related cell type, dendritic cells (DC) came to the spotlight of PPARγ
research. Dendritic cells are professional antigen presenting cells
that regulate both the innate and adaptive arms of the immune
response. Murine immature and mature splenic DCs were shown to
express PPARγ [85]. It was also shown that PPARγ was expressed in
cytokine treated humanmonocyte derived DCs (moDCs) [86–88]. Our
laboratory and others demonstrated that activation of PPARγ in
monocyte derived DCs led to an altered immune phenotype char-
acterized by increased phagocytic capacity, antigen processing and
lipid antigen presenting capacity [89–91] and [54]. Although the full
picture of how PPARγ activation led to these phenotypic changes in
DCs is not fully understood, important regulatory mechanisms were
described. In this model system, monocytes were isolated from
peripheral blood, and cultured in the presence of GMCSF and IL-4. This
led to the differentiation of monocytes into functional moDCs at day 5.
It was found that PPARγ expression was transiently induced early in
the differentiation pathway. When differentiating moDCs were
treated with the synthetic agonist, rosiglitazone, a limited gene
expression change occurred within a few hours. The rapid change in
gene expression indicated that these genes were most probably
directly regulated by ligand activated PPARγ. Several of these directly
regulated genes were found to be PPARγ dependent in other cell types
(such as FABP4/aP2, angiopoietin-related protein 4 (Angptl4), adipose
differentiation related protein (ADRP), CD36). Importantly, several
genes responsible for lipid transport/metabolism were induced, but
no key regulators of inﬂammation were found among the acutely
regulated genes. When transcriptional changes were monitored for a
longer period of time (1 day and 5 days), a new,muchmore robust set
of transcripts (about 1000 transcripts) showed altered expression
levels. It is probable that the limited set of directly regulated genes
initiated and regulated a secondary wave of transcriptional change,
which culminated in the observed phenotypic modulation of moDCs.
Such a secondary gene regulation mechanism was identiﬁed in our
laboratory. PPARγ activation in moDCs turned onmetabolic processesthat resulted in an enhanced production of retinoic acid, a known
regulator of myeloid cell differentiation and immune function.
Retinoic acid could activate its own receptors, retinoic acid receptors
(RARs), that are also members of the nuclear receptor superfamily. In
short, a concerted transition from an active PPARγ signaling to an
active RAR signaling occurred [54]. A characteristic phenotypic shift
also occurred in PPARγ activated moDCs. These cells had an enhanced
capacity to present lipid antigens to invariant natural killer T cells
(iNKT cells). This was possible because PPARγ agonist treatment
of DCs enhanced the cell surface expression of CD1d molecules by
which lipid antigens are normally presented to iNKT cells. An in-
creased lipid antigen presentation bymoDCs resulted in the activation
and proliferation of iNKT cells.
There are several questions that are raised by the results
from studying PPARγ in myeloid cells, including macrophages and
DCs. One interesting observation is that the level of PPARγ expression
and the activity of PPARγ, even when synthetic ligands are present, do
not show strong correlation. Murine peritoneal macrophages express
relatively high level of PPARγ, yet they were shown to be rather
unresponsive to ligand treatment. There must be other mechanisms,
such as the availability of other regulators, co-factors or signaling
molecules, that can regulate the responsiveness of PPARγ. This
phenomenonmight be linked to the fact that a robust PPARγ response
can be seen in these cells if they also receive simultaneous IL-4
treatment, which was thought to be mediated by an enhanced PPARγ
expression in the presence of IL-4 [92]. An alternative explanation
suggested that IL-4 treatment led to an increased production of
endogenous ligands in these cells [93]. Recent results, however, raised
the possibility that IL-4 enhanced PPARγ response in these cells via a
third mechanism. IL-4 signaling in these cells is transduced predom-
inantly by the JAK/STAT6 pathway. It was found that upon
simultaneous PPARγ and IL-4 activation of macrophages STAT6 was
able to bind PPARγ and modiﬁed its DNA binding and transcriptional
activity [45]. Another interesting feature of PPARγ signaling in
myeloid cells is that PPARγ expression and activity are often strongly
enhanced transiently during differentiation, e.g. during PMA activa-
tion of the monocytic THP1 cell line, during the in vitro differentiation
of human peripheral monocytes into DCs, or during the early stages of
murine bone marrow derived macrophage differentiation (unpub-
lished observation). The above features of PPARγ activity in myeloid
cells raise the interesting question of which are the physiologically
relevant PPARγ responsive cells in vivo. It is possible that the typical
model cell types that are used to study macrophage/DC PPARγ
activity; bone marrow derived macrophages, peritoneal macrophages
and monocyte derived macrophages/DCs (all of which require IL-4
signaling for an enhanced PPARγ response) do not represent well the
true PPARγ responsive cell populations.
Other immune cells such as T cells were shown to express PPARγ1
[94–96]. It was found that 15d-PGJ2 or TZD (ciglitazone) treatment of
murine T cell clones and enriched splenocytes inhibited antigen or
anti-CD3 ligation mediated T cell responses. Similarly, Yang et al.
reported that human peripheral T lymphocytes produced less IL-2 and
showed decreased proliferation upon (PHA) activation in the
presence of PPARγ agonist 15d-PGJ2 or troglitazone [97]. An in-
teresting interaction between macrophages and T lymphocytes
was also observed. It had been shown earlier [93] that IL-4 treatment
of macrophages induced 12/15-lipoxigenase expression in macro-
phages, which could produce potential endogenous ligands for PPARγ
in the essential fatty acid metabolism pathway. Yang et al. demon-
strated that T cells cultured in a conditionedmedium derived from IL-
4 treatedmacrophages produced signiﬁcantly less IL-2 upon anti-CD3
ligation or PHA treatment. This result suggested that the PPARγ
mediated decrease in the IL-2 production of T cells derived from a
non-cell autonomous mechanism.
PPARγ expression was also detected in B cells [98]. B cell response
to a various stimuli, including LPS stimulation or antigen receptor
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Interestingly, PPARγ+/− animals which showed no difference in the
T cell compartment when compared to wild type mice exhibited
enhanced B cell proliferative responses to stimulation. Contrary to
earlier ﬁndings, B cells of PPARγ+/− animals exhibited increased
viability.
PPARγ expression was also described in isolated primary natural
killer (NK) cells and in NK cell lines [100]. Treatment of NK cells with
15d-PGJ2 or ciglitazone was found to cause a general attenuation of
NK cell functions. The IFN-γ production, CD69 expression and the
cytolytic activity of NK cells were investigated in PPARγ ligand treated
(15d-PGJ2 and ciglitazone) and untreated cells. The inhibition of IFN-
γ production was mediated by a PPARγ, while the cytolytic activity of
NK cells was inhibited by a PPARγ independent mechanism.
5.4. PPARγ in animal models of inﬂammatory diseases
Studying PPARγ activation in isolated primary cells or in cell lines
can reveal important regulatory mechanisms by which lipids can
inﬂuence inﬂammatory responses of the investigated cell type via the
modulation of gene expression. It is, however, difﬁcult to predict the
in vivo consequences of PPARγ activation solely based on the results
obtained from in vitro studies. First, immune responses can be
regulated by many non-cell autonomous mechanisms, and activation
of PPARγ in isolated population of target cells fails to detect these
regulatory circuits. Second, it is possible that the cell types that can be
isolated and cultured in a reasonable quantity do not represent the
cell types in which in vivo activation of PPARγ has important func-
tions. For these reasons, animal models of disease have been used to
elucidate the physiological or pathological roles of PPARγ.
Inﬂammatory bowel diseases (IBD) (Crohn's disease and ulcera-
tive colitis) are inﬂammatory conditions in which the role of PPARγ
was investigated. There are several murine models for the generation
of an intestinal inﬂammation reminiscent in some aspects to different
forms of human IBD. IL-10 knockout mice develop intestinal
inﬂammation spontaneously, while intrarectal administration of
dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid
(TNBS) in wild type mice reliably induces ulcerative colitis. The
involvement of PPARγ in inﬂammatory bowel diseases was investi-
gated in several mouse models and the general picture emerged that
PPARγ activity protected from IBD. Due to the fact that PPARγ is
normally expressed in both colonic epithelial cells and in resident
macrophages of the colonic mucosa, PPARγ activity in both cell types
had the potential capacity to ameliorate disease progression. The
chemically induced inﬂammation model was used in mice heterozy-
gous for PPARγ [101], in mice with colonic epithelium speciﬁc [102],
macrophage speciﬁc [103] or T cell speciﬁc PPARγ deletion [104], or in
wild type mice in which PPARγ ligand treatment was applied to
modulate inﬂammation [105]. All above animal models showed that
deﬁciency in PPARγ resulted in an increased susceptibility to disease.
PPARγ deﬁcient animals showedmore severe disease symptoms even
in the absence of an exogenously administered PPARγ ligand. This
suggested that either unliganded PPARγ had an activity that protected
mice from the disease, or alternatively, an endogenous ligand with a
potent PPARγ agonist activity was produced in these animals. These
results raised the possibility that PPARγ agonists could be used to
ameliorate human IBD.
Experimental autoimmune encephalomyelitis is an animal model
of brain inﬂammation, in which the role of PPARγ in the regulation of
inﬂammation can be studied. EAE in rodents is accompanied by
demyelination. This characteristic of EAE makes it be a useful model
for human multiple sclerosis (MS) and acute disseminated enceph-
alomyelitis (ADEM). The ﬁrst experiments demonstrated that the
endogenous ligand 15d-PGJ2 and the TZD drugs troglitazone and
ciglitazone were able to ameliorate experimentally induced EAE
[106,107]. The decrease in disease severity and duration was, at leastpartly, due to a decrease in IL-12 production and Th1 cell differ-
entiation. In line with the above results, PPARγ heterozygous mice
developed an exacerbated disease [108] in the same EAE model. A
recent study suggested that PPARγ activation suppressed central
nervous system inﬂammation in the EAE model via the reduction of
Th17 T cell differentiation [109]. This study demonstrated both the
beneﬁcial effects of the PPARγ agonist treatment in wild type mice
and the deleterious effects of the CD4 T cell speciﬁc deletion of PPARγ.
Experimental autoimmune myocarditis is another model in
which the potential involvement of PPARγ was investigated. When
autoimmune myocarditis was induced in Lewis rats by immunization
with cardiac myosin, administration of synthetic PPARγ ligands
ameliorated disease severity. It was suggested that the inhibition of
the expansion of autoreactive T cells and a shift in the Th1/Th2
balance were responsible for the beneﬁcial effects of the agonist
treatment [110].
Two medical conditions that develop due to dysregulation of
lipid metabolism, atherosclerosis and metabolic syndrome have an
underlying chronic inﬂammatory component. Due to the fact that
PPARγ regulates lipid metabolism and also has anti-inﬂammatory
activities, it is a reasonable target in studies that dissect lipid
metabolism derived and inﬂammatory components of these diseases.
Li et al. found that rosiglitazone treatment of high fat diet fed animals
lead to a reduction of the lesion areas in high fat diet fed LDL-receptor
knockout mice. Surprisingly, the beneﬁcial effect of PPARγ activation
was detectable only in male mice [111]. The question whether the
beneﬁcial effects of PPARγwas mediated by the altered systemic lipid
homeostasis or by the altered phenotype of cells involved in the
lesions, was investigated by Collins et al. They demonstrated that the
anti-atherogenic effects of PPARγ and its beneﬁcial effects on insulin
sensitivity were uncoupled, suggesting that PPARγ ameliorated
atherosclerosis by affecting cells locally [112]. Additionally, it was
shown that bonemarrow transplantation of PPARγ−/− cells worsened
the outcome of atherosclerosis, strongly suggesting a role for PPARγ in
macrophages involved in lesion formation [113].
Unexpectedly, macrophage PPARγ was shown to be a regulator of
insulin sensitivity in two metabolic studies [80,114]. It has been
known for long from bothmurine studies and humanmedical practice
that ligand activation of PPARγ improves insulin sensitivity. Original-
ly, it was assumed that the beneﬁcial effects of ligand activation were
mediated by PPARγ in one of the major target tissues of glucose and
lipid metabolism, such as muscle, fat or liver. Interestingly, the loss of
PPARγ in hematopoietic cells was found to lead to insulin resistance.
This suggested that inﬂammation is a component in developing
insulin resistance in the mouse and macrophage PPARγ deletion
exacerbated this inﬂammation. It must be added, however, that a
similar study [115] found preserved glucose tolerance in high-fat-fed
C57BL/6 mice transplanted with PPARγ−/−, PPARβ/δ−/− or LXRα−/−
(liver X receptor alpha, another nuclear receptor with a role in lipid
metabolism) hematopoietic cells. It was also found that the main site
of the insulin sensitizing activity of ligand activated PPARγ was, in
fact, adipose tissue [116]. Because of these contradicting results
further studies are needed to clarify the contribution of macrophage
PPARγ to the development of insulin resistance.
5.5. PPARγ and inﬂammation in humans
Human PPARγ mutations and single nucleotide polymorphisms
(SNPs) were associated with metabolic and inﬂammatory diseases.
Barroso et al. examined all the coding exons of PPARγ 1 and 2 in 85
unrelated patients with severe insulin resistance [117]. They
identiﬁed two heterozygous missense mutations of PPARγ ligand-
binding domain (P467L and V290M) in three patients. All three
patients had type 2 diabetes mellitus and hypertension, suggesting
the important role of PPARγ in regulation of insulin sensitivity,
glucose homeostasis and blood pressure. Agostini et al. described
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patients. These mutations made PPARγ unable to bind DNA and acted
in a dominant-negative fashion [118]. Since the canonical function of
PPARγ is the regulation of glucose and lipid metabolism, it is more
than probable that these phenotypes were caused by the impaired
metabolism in these patients and not because the loss of PPARγ
contributed to an enhanced inﬂammation in metabolic disease.
Several single nucleotide polymorphisms (SNPs) of PPARγ were
identiﬁed. The most commonly studied SNP, Pro12Ala, has ﬁrmly
been demonstrated to inﬂuence metabolic status of patients [119].
Additionally, evidence is accumulating suggesting that PPARγ SNPs
also inﬂuence inﬂammatory diseases. Oh et al. showed that the com-
bination of the major allele of the non-synonymous Pro12Ala SNP
with the major allele of the synonymous His449His polymorphism
was associated with the development of asthma, while the frequency
of the major Pro12Ala allele in combination with the minor His449His
allele was signiﬁcantly lower in patients with asthma compared to
healthy controls [120]. Penyige et al. showed that major allele of
the His447His polymorphisms had protective role in COPD while the
minor His447His allele was associated with development of COPD
[121]. Additionally, association of the minor allele of the same SNP
(referred to as C161T in the study)with ulcerative colitis in the central
Chinese but not Dutch IBD population was found [122]. In summary,
genetic variations in PPARγ, which have only a slight effect on the
function/expression level of the receptor, can have statistically
demonstrated effect on several chronic inﬂammatory conditions.
Similar studies in other inﬂammatory diseases are expected to emerge
in the near future and they hold the potential to corroborate or
refute models of PPARγ functions that were formulated based on
cellular or animal studies.
6. PPARα
PPARα expression was predominantly found in the liver, but was
also found to be expressed in cardiac myocytes, proximal tubular
epithelial cells of kidney, skeletal muscle, large intestine epithelium,
endothelial and smoothmuscle cells as well as immune cells including
macrophages, lymphocytes and granulocytes [5,123–126]. It is a key
regulator of peroxisomal andmitochondrial β-oxidation of fatty acids,
ketone body synthesis and systemic lipid metabolism. Similarly
to PPARγ, there is an accumulating body of data suggesting that
PPARα is not exclusively a metabolic regulator, but also have potent
anti-inﬂammatory activities.
6.1. Mechanisms of PPARα activation
It is important to note that PPARα is the only subtype of PPARs
whose candidate endogenous ligands are indeed most likely bona ﬁde
ligands. As already mentioned, dietary fatty acids can bind to and
activate PPARα. Consequently, there is an intriguing possibility that
our diet directly inﬂuences our immune system by activating
transcription factors and therefore regulating gene expression. The
classical model described in the PPARγ section for agonist activated
PPAR transactivation is also applicable to PPARα. Similarly to PPARγ,
there is hardly any immunologically relevant gene whose positive
regulation by PPARα can be explained by the classical, agonist
mediated transactivation model. The only notable exception may be
the case of IL-4 regulation in lymphocytes [127]. In this experiment,
gemﬁbrozil treatment attenuated the symptoms of experimental
autoimmune encephalomyelitis (EAE) in mice. It was observed that
the beneﬁcial effect of the gemﬁbrozil could be detected only in wild
type but not in IL-4 knockout animals. Because it was known that
gemﬁbrozil treatment enhanced IL-4 production, the idea was tested
if gemﬁbrozil was a direct regulator of IL-4 expression. Chromatin
immunoprecipitation (ChIP) experiments detected PPARα binding tothe identiﬁed PPRE element in the promoter region of IL-4 and IL-5
genes.
Similarly to PPARγ, PPARα can also regulate gene expression by a
variety of transrepression mechanisms. Ligand dependent transre-
pression was demonstrated in aortic smooth muscle cells [68], where
treatment with LPS normally results in IL-6 release. Treatment of
aortic explants with fenoﬁbrate strongly decreased IL-6 production. It
was found that liganded PPARα directly bound key transcription
factors that are known to regulate IL-6 expression, such as the NF-κB
subunit p65, c-Jun and c-AMP response element binding protein-
binding protein (CBP).
Interestingly, a new twist in the mode of transrepression was
described by Bougarne et al. [128]. Glucocorticoid receptor alpha
(GRα) is yet another nuclear receptor that has a well documented
anti-inﬂammatory activity. Its ligands, glucocorticoids, are important
drugs in treating inﬂammatory conditions. Both GRα and PPARα can
inhibit NF-κB mediated inﬂammatory gene expression by transre-
pressing NF-κB. It was found that cells that received simultaneous
PPARα and GRα ligand treatments exhibited an increased, additive
transrepression of NF-κB. At the same time, ligand activated PPARα
could negatively interfere with the transactivation capacity of GRα on
its target sequences. These results raised the questions if PPARα,
activated by endogenous ligands, is also able to potentiate GRα in vivo,
and if PPARα agonists could be used in combination therapies with
glucocorticoids to alleviate inﬂammatory conditions.
6.2. Alternative activation of PPARα
Several posttranslational modiﬁcations were described for PPARα.
Insulin mediates the phosphorylation of Ser12 and Ser21, which
enhance the transactivation capacity of PPARα [129]. Other phos-
phorylation mechanisms, by the p38 MAPK or protein kinase C (PKC)
pathways, were also described. Interestingly, inhibition of PKC had a
dual effect on PPARα. PKC inhibition decreased transactivation
capacity of PPARα, but enhanced its transrepression activity [130].
6.3. Cellular model systems to study the inﬂammatory functions of
PPARα
The expression of PPARα has been reported in several immuno-
logically relevant cell types. In human monocyte derived macro-
phages it was found that ligand activation of PPARα induced
apoptosis [126]. This pro-apoptotic effect was even more pronounced
if the cells were pretreated with INF-γ or TNFα. Jones et al.
demonstrated that PPARαwas also expressed in T and B lymphocytes,
and the expression of PPARα declined when lymphocytes were
activated [125]. The ligand activation of PPARα in these cells led to a
measurable transactivation activity and the transrepression of NF-κB.
Ligand independent transrepression activity of PPARα was found in
CD4+ T cells, where unliganded PPARα suppressed the phosphory-
lation of p38MAP kinase. PPARα ligand treatment of CD4+ cells led to
the relaxation of this suppression effect, and increased p38 MAP
kinase phosphorylation [131]. As mentioned above, ligand activation
of PPARα in murine T lymphocytes revealed that IL-4 and IL-5 are
possible PPARα target genes [127]. Langerhans cells were also shown
to express PPARα and pharmacological activation of PPARα inhibited
Langerhans cell maturation.
6.4. PPARα in animal models of inﬂammatory diseases
The ﬁrst report that suggested that PPARα could control
inﬂammation [9] studied leukotriene B4 (LTB4) induced inﬂamma-
tion in wild type and PPARα knockout mice. LTB4 is a locally
generated lipid inﬂammatory agent that initiates and coordinates
inﬂammation by activating its cell surface receptor. Alternatively, it
can also bind to and activate PPARα. The activation of PPARα
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molecules, including LTB4 itself. The idea was tested if PPARα,
activated by LTB4, could negatively regulate inﬂammation by the
enhanced metabolism of arachidonic acid (and LTB4), which would
result in a limited duration of inﬂammatory responses. The mouse
ear-swelling test (MEST) was used in which the inﬂammatory
agents were locally applied to the ear and ear thickness wasmeasured
for the quantitation of inﬂammatory response. PPARα−/− mice
showed prolonged inﬂammation when arachidonic acid or its
metabolite LTB4 were used to trigger inﬂammation, but the same
effect did not occur when a distinct inﬂammatory agent, phorbol
esther was used. Due to the fact that the LTB4 is not only an inﬂam-
matory molecule but also an efﬁcient ligand for PPARα, the results
suggested the existence of a negative feedback mechanism limiting
the duration inﬂammation.
Interestingly, PPARα showed a dual role in the LPS induced
endotoxic shock model [132]. While synthetic agonist treatment of
isolated macrophages decreased LPS induced TNFα release, whole
body treatment with fenoﬁbrate in LPS treated mice increased the
systemic level of TNFα. The proposed explanation for this contradic-
tion was that systemic PPARα activation altered whole body lipid
homeostasis, which resulted in an increased propensity to develop
endotoxic shock. This could not be offset by a PPARα mediated
repression of TNFα in macrophages.
Other animal experimental models also suggested that PPARα has
an anti-inﬂammatory role. In a murine model of human asthma [133]
mice were sensitized and challenged with aerosol nebulization of
ovalbumin derived antigen (OVA). PPARα deﬁcient mice showed
increased eosinophilia, airway hyperresponsiveness, increased IL-6,
IL-13 and eotaxin production in lung extracts as well as enhanced
serum concentration of antigen-speciﬁc IgE. In addition, PPARα
activation inhibited IL-5 and eotaxin induced migration and antibody
dependent cellular cytotoxicity of human eosinophils in vitro.
Delayre-Orthez et al. examined the role of PPARα in another airway
inﬂammation model [134]. Airway inﬂammation was induced in wild
type and PPARα knockout mice by intranasal instillation of LPS. PPARα
deﬁcient mice exhibited increased number of neutrophils and macro-
phages and released higher level of TNFa, MIP-2 (macrophage
inﬂammatory protein-2), MCP1 (monocyte chemoattractant protein
1) and KC/CXCL1 (keratinocyte chemoattractant) in the bronchoalve-
olar lavage ﬂuid. In addition, the PPARα ligand fenoﬁbrate inhibited LPS
induced macrophage and neutrophil inﬁltration, decreased cytokines
levels and MMP-2 and MMP-9 (matrix metalloproteinase) activity in
wild type but not knockout mice. This demonstrated that the effects of
fenoﬁbrate were speciﬁcally mediated by PPARα.
In the carrageenan-induced paw edema and carrageenan-induced
pleurisy models of inﬂammation, Cuzzocrea et al. found that deletion
of PPARα led to an increased paw edema and pleural exudate
formation and neutrophil inﬁltration [135]. Furthermore, PPARα−/−
animals exhibited enhanced production of TNFα, IL-1β in the pleural
exudate. Interestingly, D'Agostino et al. demonstrated that the acute
intracerebroventricular administration of an endogenous PPARα
ligand, palmitoylethanolamide, had potent anti-inﬂammatory effects
in the carrageenan-induced paw edema model when palmitoyletha-
nolamide was administered prior to the carrageenan injection [136].
Importantly, intracerebroventricular administered palmitoylethano-
lamide failed to modulate inﬂammation in PPARα knockout mice.
Again, this proved that the anti-inﬂammatory effects of palmitoy-
lethanolamide were mediated by PPARα.
Several experiments suggest a potential role of PPARα in colonic
inﬂammation and maintenance of mucosal tissue homeostasis. In the
IL-10 knockout mice model, Lee et al. demonstrated that the PPARα
ligand fenoﬁbrate could decrease colonic INF-γ and IL-17 expression
and leukocyte inﬁltration [137]. PPARα was expressed in lympho-
cytes, macrophages and colon epithelial cells in this model. Therefore
it was not determined in which cell type PPARα activation wasrequired for the amelioration of the disease. Similarly, in the DSS
induced colitis model, administration of another synthetic PPARα
ligand, WY-14643, resulted in a reduced release of inﬂammatory
cytokines (including INF-γ, IL-1β, IL-6 and TNFα) [138].
Other studies investigated the role of PPARα in mouse model of
atopic dermatitis. Atopic dermatitis can develop in mice following
topical sensitization and challenge with ovalbumin or oxazolone.
Staumont-Sallé et al. described that PPARα deﬁcient mice showed
enhanced dermal recruitment of inﬂammatory cells, IgG2a and IgE
production, epidermal thickening as well as lung inﬂammation and
airway hyperresponsiveness following sensitization with ovalbumin
[139]. In addition, topical application of the PPARα ligand, WY-
14643, signiﬁcantly decreased antigen-induced skin inﬂammation in
the ovalbumin induced atopic dermatitis model. In the oxazolone
induced atopic dermatitis model, the topical activation of PPARα by
WY-14643 could normalize the structure of epidermis, signiﬁcantly
improved barrier function of the skin and increased stratum corneum
hydration as well as reversed the immunologic abnormalities.
Furthermore, PPARα activation decreased epidermal production of
inﬂammatory cytokines in both ovalbumin and oxazolone induced
atopic dermatitis [140].
The role of PPARα in experimental autoimmune encephalomyelitis
was also investigated.
Lovett-Racke et al. demonstrated that PPARα agonists could be
used to ameliorate disease progression [141]. The oral administration
of gemﬁbrozil and fenoﬁbrate inhibited clinical signs of experimental
autoimmune encephalomyelitis and also suppressed antigen speciﬁc
T cell proliferation in a dose dependent manner. The PPARα agonists
also increased the production of the Th2 cytokine IL-4 and inhibited
the release of the Th1 speciﬁc IFN-γ. The agonists also decreased nitric
oxide (NO) production by murine microglial cells and enhanced IL-4
production and suppressed IFN-γ secretion of cultured human T cells.
It must be noted, however, that Dasgupta et al. reported that the
gemﬁbrozil induced reduction of clinical signs of EAE, demyelination
and inﬁltration of mononuclear cells in the central nervous system,
were independent of PPARα [142]. In a third study, male but not
female mice exhibited enhanced clinical signs of inﬂammation and
increased numbers of inﬂammatory brain lesions in PPARα−/−
animals. PPARα expression in CD4+ T cells was found to be higher
in male than in female mice, suggesting sex speciﬁc role of PPARα in T
cells mediated autoimmunity [143,144]. In addition, Xu et al. demon-
strated the effect of activated PPARα on primary mouse astrocytes, a
cell type implicated in the pathology of MS and EAE. Fenoﬁbrate
and WY-14643 were able to inhibit the NO production of astrocytes
stimulated by LPS in a dose-dependent manner. Furthermore, feno-
ﬁbrate treatment of astrocytes decreased the LPS induced secretion of
TNFα, IL-1β and IL-6 [145].
The liver is the centre of the lipid and carbohydrate metabolism as
well an important regulator of inﬂammation. Acute phase proteins are
among the key molecules by which liver is able to modulate
inﬂammation are. PPARα was demonstrated to inﬂuence systemic
inﬂammatory responses by regulation of the acute phase response.
The PPARα ligand fenoﬁbrate inhibited the expression of IL-6 induced
acute phase response proteins including ﬁbrinogen-a, -b and -g,
serum amyloid A and haptoglobin in the liver of wild type but not in
PPARα knockout mice. As an additional proof for the role of PPARα in
acute phase response, fenoﬁbrate treated hyperlipidemic patients
were shown to have decreased plasma concentration of ﬁbrinogen, C-
reactive protein, serum amyloid A, plasminogen and a2macroglobulin
[146].
PPARα has the potential to affect atherosclerosis at two levels.
First, PPARα is a regulator of lipid metabolism, and the loss of PPARα
function causes higher than normal levels of atherogenic lipoproteins.
Alternatively, PPARα could impact the inﬂammatory component of
atherosclerosis. Tordjman et al. demonstrated that PPARα/ApoE
double knockout mice showed higher serum level of atherogenic
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insulin resistance and blood pressure as compared to PPARα+/+ ApoE
−/− littermates [147]. Interestingly, Babaev et al. examined the role of
PPARα in bone marrow-derived cells in atherosclerosis by recon-
stituting LDLR knockout mouse hematopoietic tissue with bone
marrow from PPARα knockout and wild type mice. LDLR−/− mice
following bonemarrow transplantation from PPARα−/−mice showed
increased size of atherosclerotic lesions in aorta compared to LDLR−/−
mice with wild type derived bonemarrow, suggesting complex role of
PPARα in development of atherosclerosis [148].
Similarly to PPARγ, it is possible that PPARα activity also
modulates obesity associated inﬂammation either through its meta-
bolic activity or anti-inﬂammatory effects. Induction of obesity with
high-fat diet in PPARα knockout or wild type mice suggested
that PPARα protected against obesity-induced chronic inﬂammation
in the liver. Plasma markers of liver injury and inﬂammation,
including serum amyloid A and alanine aminotransferase activity,
were increased in high-fat diet fed PPARα−/−, but not in wild-type
animals [149].
7. PPARβ/δ
Among the PPARs, PPARβ/δ has been the least studied subtype so
far. However, important advances were made in recent years in
understanding the metabolic and inﬂammatory functions of PPARβ/δ.
PPARβ/δ is expressed almost ubiquitously [59], with the highest
level of expression found in colon, small intestine, liver and kera-
tinocytes. PPARβ/δ is a general regulator of fatty acid oxidation in
many tissues.
7.1. The role of PPARβ/δ
The involvement of PPARβ/δ in the regulation of lipid metabolism
has been well established based on knockout and overexpression
studies in transgenic mice [49,150,151]. PPARβ/δ knockout mice are
smaller, both pre-, and postnatally, than wild type animals. Reduced
offspring numbers were also found, due to a placental defect.
Overexpression of a constitutively active PPARβ/δ in white adipose
tissue reduced adiposity, most probably to the enhanced level of
fatty acid oxidation. The metabolic pathways that were under the
regulation of PPARβ/δ included fatty acid metabolism, mitochondrial
respiration and programming of the muscle ﬁber type. The analysis of
the full body knockout of PPARβ/δ revealed that it also regulated the
inﬂammatory reaction during skin wound healing [150] and [151].
Recently, several studies reported the role of PPARβ/δ in different
types of inﬂammation.
7.2. Cellular model systems to study the inﬂammatory functions of
PPARβ/δ
Several inﬂammatory cell types express PPARβ/δ. PPARβ/δ activity
in macrophages was thoroughly studied due to the connection of
PPARβ/δ to atherosclerosis. Several inﬂammatory genes are regulated
by PPARβ/δ in murine macrophages, e.g. monocyte chemoattractant
protein 5 (MCP-5/CCL12), IL-1β, TNFα, IL-6 and VCAM-1 (vascular cell
adhesion molecule 1) [152,153]. The main form of PPARβ/δ activity in
these cells is proposed to be a ligand-independent transrepression, in
which unliganded PPARβ/δ binds and sequesters the repressor
molecule B-cell lymphoma-6 (BCL-6). Upon PPARβ/δ ligand activa-
tion, however, PPARβ/δ releases BCL-6, which then can repress the
expression of inﬂammatory genes.
7.3. PPARβ/δ in animal models of inﬂammatory diseases
Skin inﬂammation and wound healing was the ﬁrst inﬂammatory
model in which the role of PPARβ/δ was investigated. Michalik et al.found that all PPARs were expressed in the skin during fetal
development of mice [151]. Interestingly, although the expression of
all PPARs in healthy adult epithelium declined, PPARα and PPARβ/δ
were rapidly reactivated in adult epidermis upon a variety of
inﬂammatory stimuli, including local tetradecanoyl phorbol acetate
(TPA) application on skin and skin wounding. The two PPARs affected
different stages of wound healing; PPARα was important in the
regulation of the early inﬂammatory reaction, whereas PPARβ/δ
regulated keratinocyte proliferation. PPARα−/− animals showed
impaired inﬁltration of immune cells to the site of the injury, which
resulted in delayed healing. On the other hand, PPARβ/δ+/−
heterozygous animals exhibited a hyperproliferative keratinocyte
reaction.
The involvement of PPARβ/δ in atherosclerosis was also investi-
gated [154]. It was found that PPARβ/δ deﬁciency in hematopoietic
cells protected against atherosclerosis. Interestingly, it seems that
the loss of PPARβ/δ in foam cells reduced atherosclerotic lesion
areas not by themodulation of lipid metabolism but the regulation of
the inﬂammatory component of atherosclerosis. The expression of
several inﬂammatory genes was decreased in PPARβ/δ deﬁcient
macrophages, including MMP9 (matrix metalloproteinase 9) and IL-
1β. According to the proposed mechanism for the observed anti-
inﬂammatory role of PPARβ/δ, a ligand independent transrepression
of BCL-6 was proposed. Also a ligand independent transrepression
mechanism was proposed for the protective effect of PPARβ/δ in DSS
induced colitis. The level of IFN-γ, TNF-α and IL-6 was increased in
PPARβ/δ deﬁcient animals [155].
Interestingly, PPARβ/δ also inﬂuenced the development of alterna-
tively activated macrophages (M2 macrophage). Arg1, an M2 marker
gene that is under PPARγ regulation in murine myeloid cells [80], was
also regulated by PPARβ/δ [156,157]. In fact, a complementary
regulation by both PPARγ and PPARβ/δ was needed to ensure Arg1
expression. Moreover, the M1 macrophage mediated uptake of
Leishmania major was impaired in cells that received PPARβ/δ ligand
treatment. These results suggested again that PPARγ and PPARβ/δ, but
not PPARα, are regulators of the M2 macrophage development.
Another animal model in which PPARβ/δ shows overlapping
functions with other PPARs is EAE [143]. In the EAE model, PPARβ/δ−/−
animals displayedmore inﬂammatory foci in the central nervous system.
This was partly due to an expanded population of CD4+ cells that
produced both IFN-γ and IL-17. PPARβ/δ ligand treatment of wild type
CD4+ cells in serum-free medium resulted in a decreased production of
IFN-γ by wild type but not PPARβ/δ−/− cells.
Recently, another aspect of the anti-inﬂammatory role of PPARβ/δ
was revealed [158]. PPARβ/δwas found to be necessary for the timely
clearance of apoptotic cells. PPARβ/δ deﬁciency caused a delay in the
uptake, while PPARβ/δ ligand treatment in wild-type mice caused an
enhanced uptake of apoptotic cells. C1q, a component of the classical
complement activation pathway was found to be a direct target gene
of PPARβ/δ. As a result of the abnormal sensing of apoptotic cells in
PPARβ/δ−/− animals, these mice developed a lupus erythematosus-
like autoimmune disease.
8. Summary and perspectives
PPARs are a truly fascinating set ofmolecules. They represent a direct
link between changes in the intracellular lipidmilieu and the expression
of the genome. It is intriguing to see how literature on the activity of
these transcription factors is broadening, largely due to the availability
of synthetic ligands, animal models and drugs acting via these proteins.
However, in spite of the wealth of the sometimes conﬂicting pieces of
information available, key issues are still unresolved. These include the
true nature of ligand(s) and the way it/they are generated, the
predominant mechanisms of action, the genomic loci regulated along
with target genes and the tissue and disease speciﬁc contribution of the
individual receptors to cellular function and diseases. Further progress
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as in vivo ligand detection and determination and single cell biophysical
and microscopic technologies to detect ligand–receptor and ligand–co-
factor interactions in vivo. Systematic efforts to determine genomic
binding sites, the identity of co-binding transcription regulators and
associated histone marks to reveal the predominant mechanisms of
action including the often overlooked transcriptional repression are also
needed. Finally the ﬁeld needs to go down the painstaking path of
evaluating the role of each of the three receptors in individual cell types
using advanced mouse genetics approaches combined with disease
models to truly deﬁne the regulated gene sets and pathways. These
along with clinical advances can provide us with the insights into the
intricate relationship between lipids, receptors and inﬂammation.
Identiﬁcation of mechanisms of endogenous ligand generation and the
direct target genes of each of the receptors in every relevant tissue
would be particularly useful in order to identify new therapeutic targets
for the biotech and pharma industries. Such new developments would
provide further and a much needed boost for the ﬁeld.
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